Lagevrio vs. Paxlovid for Early COVID-19 Treatment

Lagevrio and Paxlovid are prescription antiviral medicines used early in COVID-19 to lower the chance of severe illness in people at higher risk. Paxlovid is generally the preferred oral option because it has stronger evidence of benefit, while Lagevrio may be considered when Paxlovid and other suitable treatments cannot be used.

Lagevrio vs Paxlovid at a Glance

Lagevrio and Paxlovid are oral antiviral medicines for people with mild-to-moderate COVID-19 who are more likely to become seriously ill. They are not interchangeable, and the best choice depends on the individual’s medical history, current medicines, pregnancy considerations, and how soon treatment can begin. For many eligible adults and adolescents, clinicians consider Paxlovid first because evidence supporting its ability to reduce severe COVID-19 outcomes is stronger.

Feature	Paxlovid	Lagevrio
Active medicine	Nirmatrelvir with ritonavir	Molnupiravir
How it works	Blocks a viral enzyme needed for SARS-CoV-2 to multiply; ritonavir helps maintain nirmatrelvir levels	Introduces copying errors as the virus replicates, limiting its ability to multiply
Who may be eligible	Adults and certain children aged 12 years and older who meet weight requirements and are at higher risk	Adults aged 18 years and older who are at higher risk, when preferred options are unsuitable or unavailable
When to start	As soon as possible, within 5 days of symptom onset	As soon as possible, within 5 days of symptom onset
Main practical concern	Potentially serious interactions with many medicines	Pregnancy and reproductive precautions; lower priority than preferred treatments
Kidney or liver considerations	May need dose adjustment or may not be appropriate depending on kidney and liver function	Usually has fewer medication-interaction concerns; a clinician still reviews overall health

Both treatments are intended for early outpatient care, not for people who are already hospitalized because of severe COVID-19. They do not provide immediate relief of symptoms, and they should not be saved for future use. A positive COVID-19 test, compatible symptoms, and a timely clinical assessment help determine whether antiviral treatment is appropriate.

How a Clinician Tells Them Apart

The first question is whether treatment is needed at all. Healthy people with mild COVID-19 often recover with rest, fluids, and symptom relief alone. Antiviral treatment is most relevant for people with factors linked to a higher likelihood of severe disease, such as older age, weakened immunity, certain chronic medical conditions, or multiple health risks. Vaccination status may be considered, but it does not automatically rule treatment in or out.

Next, the clinician confirms the timeline. Both Paxlovid and Lagevrio work best when started early, generally no later than 5 days after symptoms begin. A person should contact a healthcare professional promptly after developing symptoms or receiving a positive test result, rather than waiting to see whether symptoms become worse. Waiting may mean the treatment window closes.

The medication review is especially important for Paxlovid. Ritonavir affects liver enzymes that process many medicines, so it can raise or lower levels of other drugs in ways that may be harmful. The clinician or pharmacist checks every prescription medicine, over-the-counter product, vitamin, herbal supplement, and recreational substance. Some interactions can be managed by temporarily holding, changing, or closely monitoring another medicine, while others mean Paxlovid should not be used.

What Makes Paxlovid the Usual First Choice

Paxlovid combines nirmatrelvir, which interferes with a protein the COVID-19 virus needs to reproduce, with ritonavir, which slows the breakdown of nirmatrelvir in the body. When prescribed for an eligible person early in infection, it can reduce the likelihood of progression to severe illness. It is taken by mouth for a short treatment course and is available only with a prescription.

Paxlovid is generally authorized or approved for adults with mild-to-moderate COVID-19 who are at increased risk of severe illness, and it may also be available for certain higher-risk adolescents aged 12 years and older who meet weight requirements. Eligibility rules and local availability can vary by country, so the treating clinician confirms the relevant guidance. It is not a routine treatment for every positive COVID-19 test.

Kidney function matters because the Paxlovid dose may need adjustment in some people with reduced kidney function. Severe kidney or liver disease can make treatment more complex or unsuitable, depending on the circumstances. A clinician may use recent laboratory results when available, but should not delay a time-sensitive decision unnecessarily when a safe assessment can be made from the person’s history and records.

When Lagevrio May Be Considered

Lagevrio contains molnupiravir, an antiviral that disrupts the virus as it copies its genetic material. It is used for mild-to-moderate COVID-19 in higher-risk adults when other preferred treatment options are not accessible or are not clinically appropriate. It is not authorized for children or adolescents because of concerns related to bone and cartilage growth.

A major reason a clinician may consider Lagevrio is that Paxlovid has an interaction with a necessary medicine that cannot be safely paused, substituted, or monitored. Lagevrio may also be discussed when a person cannot use other preferred treatments because of individual medical factors or practical access barriers. This does not mean it is automatically the best alternative; the clinician weighs the expected benefit and possible risks for that specific person.

Lagevrio is not recommended during pregnancy because its potential effects on a developing fetus are uncertain and concerning in preclinical research. People who are pregnant, could be pregnant, or are trying to conceive should discuss safer alternatives promptly with a clinician. Healthcare professionals also discuss contraceptive precautions and reproductive considerations with patients who may receive this medicine, following the current local product information.

What to Do in Common COVID-19 Treatment Situations

If symptoms began within the past 5 days and the person has risk factors: They should contact a doctor, urgent-care service, or pharmacist promptly. They should have a list of all medicines ready, including inhalers, blood thinners, heart medicines, seizure medicines, transplant medicines, sleep medicines, supplements, and herbal products. This allows the care team to assess Paxlovid interactions quickly and decide whether adjustments are safe.

If Paxlovid is not suitable: The clinician may assess Lagevrio or another treatment approach. In some settings, a short course of intravenous remdesivir is a preferred alternative for appropriate patients and has a different treatment window. The choice depends on medical eligibility, timing, access to care, and local clinical guidance rather than personal preference alone.

If the person is pregnant, immunocompromised, has kidney or liver disease, or takes many medicines: They should seek individualized advice rather than assuming an antiviral is unsafe or unavailable. These situations often require a more detailed review, but treatment can still be possible. The goal is to identify an option that balances protection from severe COVID-19 with medication safety.

Side Effects, Rebound, and Safe Self-Care

Like all medicines, both antivirals can cause side effects. Paxlovid can cause changes in taste, diarrhea, muscle aches, or increased blood pressure in some people, while Lagevrio can cause diarrhea, nausea, or dizziness. Most side effects are mild, but a patient should contact their care team if symptoms are persistent, troublesome, or unexpected.

Some people experience a return of symptoms or a new positive test after initially improving, often called COVID-19 rebound. Rebound can happen after Paxlovid and can also occur as part of the natural course of COVID-19, including in people who have not taken antiviral treatment. A return of symptoms does not usually mean the medicine failed or that an additional course is needed; a clinician should guide any further treatment decisions.

During recovery, people should rest, drink fluids, eat as tolerated, and use symptom-relief medicines only as appropriate for their health conditions. They should follow local public-health guidance on staying home, testing, masking, and limiting contact with others while contagious. Vaccination remains an important way to reduce the risk of severe COVID-19, even though vaccinated people may still occasionally need antiviral treatment.

When to Seek Medical Care

A person with COVID-19 should seek urgent medical help for trouble breathing, persistent chest pain or pressure, new confusion, fainting, inability to stay awake, bluish or gray lips or face, or other signs of severe illness. These symptoms require prompt assessment and should not be managed by waiting for an antiviral prescription. Emergency warning signs can vary, particularly in children, older adults, and people with chronic illness.

People at higher risk of severe COVID-19 should contact a healthcare professional soon after symptoms begin or after a positive test, even if symptoms feel mild. Early contact is important because both Paxlovid and Lagevrio have a limited window for starting treatment. A clinician can also advise whether home monitoring, such as checking temperature or oxygen levels when appropriate, is useful.

Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals can assess COVID-19-related health needs and provide individualized treatment planning for international patients. For anyone considering an antiviral, the safest next step is a timely discussion with a qualified clinician or pharmacist who can review the complete medical history and medication list.

Frequently asked questions